PBM Reform Gives Employers Data, Not Decisions
Federal PBM reform is giving employer health plans something they have needed for years: more visibility into the money moving through the pharmacy benefit. That is progress. It is not the same as savings.
A timely Sequoia overview of 2026 PBM reform makes the business issue clear. New federal requirements expand reporting, disclosure, audit rights, and fiduciary oversight. The underlying federal PBM transparency statute calls for information that includes rebates, discounts, price concessions, prescription volume, and amounts passed through to the plan sponsor.
Here is the plain-English summary: employers should receive more facts about PBM economics. The harder question is whether anyone inside the company has a process for using those facts before the next contract is signed.
Why This Matters More in a Self-Funded Plan
In a self-funded health plan, the employer is not just paying a premium and walking away. The company funds claims, selects vendors, approves contract terms, and carries fiduciary responsibilities. When pharmacy costs rise, the employer's own plan dollars are at stake.
That makes PBM reporting useful, but only if it can answer business questions:
- How much did the plan pay for each drug after every rebate, fee, and credit?
- How much compensation stayed with the PBM or an affiliated company?
- Did the formulary steer members toward the lowest net-cost option?
- Did the plan receive everything the contract promised?
- What should change at renewal because of what the data shows?
For a Midwest manufacturer, contractor, dealership group, or professional firm, this is not a Washington policy exercise. It is purchasing discipline. Pharmacy can be one of the fastest-moving parts of the health plan, and a weak contract can quietly turn revenue into someone else's margin.
More Information Creates More Responsibility
Leaders sometimes assume a disclosure rule will make the market fix itself. It will not.
A report can arrive on time and still sit unread. A rebate total can look impressive without showing whether the plan's net cost was competitive. A vendor can describe its model as transparent while the contract limits audit rights, excludes affiliates, or uses definitions that are difficult to test.
The real opportunity is to connect four things that are often reviewed separately:
- The PBM contract.
- The claims and utilization data.
- The compensation and rebate disclosures.
- The renewal recommendation.
If those four items do not reconcile, leadership does not yet have a decision-ready picture.
A Practical PBM Decision File
CEOs and CFOs do not need to become pharmacy technicians. They do need a short record showing what was reviewed, what was found, and why the company chose its path.
Start with this checklist:
- Contract map: List every entity earning money from the arrangement, including affiliates and subcontractors.
- Rebate reconciliation: Compare amounts received by the PBM with amounts credited to the plan.
- Claim-level test: Sample high-cost and high-volume drugs and calculate the plan's net cost.
- Formulary review: Identify cases where a higher-rebate drug may not be the lowest-cost choice for the plan and member.
- Audit-rights check: Confirm who can audit, what data is available, how far back the review can go, and what happens when an error is found.
- Renewal action: Record the contract change, vendor comparison, or clinical strategy that follows from the findings.
This turns compliance information into a purchasing tool. It also gives plan fiduciaries a record that the company did more than collect reports.
Where Superior Insurance Advisors Fits
Superior Insurance Advisors helps employers connect vendor contracts, claims information, and renewal strategy in plain English. The value is not another thick report. It is a clear view of where the money goes, which terms deserve pressure, and what leadership should decide next.
For employers evaluating self-funding or already operating a self-funded plan, that review can expose questions hidden by the usual renewal comparison. Paul H. Flowers Jr. brings the conversation back to business fundamentals: control, cash flow, accountability, and a decision the leadership team can defend.
The Decision Question
Before your next PBM renewal, ask one question:
If the new disclosures arrived tomorrow, who would compare them with our contract and claims, and what decision could they actually change?
If the answer is unclear, the next step is not to wait for more reform. It is to build the review process now. Learn more or start a conversation at Paul.Health.